Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
ToolGen Incorporated specializes in gene editing technologies, particularly CRISPR-based solutions for therapeutic applications. The company operates primarily in the United States and has a strong patent portfolio that provides a competitive edge in the rapidly evolving biotech sector.
ToolGen generates revenue through the sale of gene editing therapeutics, primarily targeting genetic disorders. The company leverages its proprietary CRISPR technology to establish partnerships with pharmaceutical firms, enhancing its revenue through research collaborations and licensing agreements.
Advancements in CRISPR technology and successful clinical trial results
Regulatory approvals for new gene therapies
Partnership announcements with major pharmaceutical companies
Market adoption rates of gene editing therapies
Regulatory changes affecting gene editing technologies
Technological disruption from competing gene editing methods
Emergence of new competitors with superior gene editing technologies
Potential patent disputes that could limit market access
High cash burn rate due to ongoing R&D expenditures
Dependency on external funding for continued operations
moderate - The demand for healthcare innovations is somewhat insulated from economic cycles, but funding for biotech ventures can be affected by broader economic conditions.
Higher interest rates could increase the cost of capital for ToolGen, impacting its ability to finance R&D activities and potentially slowing growth.
minimal - The company currently has no debt, reducing its exposure to credit market fluctuations.
growth - Investors are likely attracted to the potential for high returns from innovative biotech solutions.
high - The stock has exhibited significant volatility due to the speculative nature of biotech investments.